Navigation Links
Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction
Date:10/27/2010

TEMPE, Ariz., Oct. 27 /PRNewswire/ -- Intrinsic Bioprobes today announced that the United States Patents and Trademark Office has issued US Patent 7,816,095 covering novel blood protein biomarkers related to cardiovascular disease. This patent is first of a series of patent applications that cover specific human protein variants as biomarkers with clinical utility.

"The biomarkers were discovered using Intrinsic Bioprobes' unique Mass Spectrometric Immunoassay technologies," says Urban Kiernan, Ph.D., the Director of Biomarker Discovery at Intrinsic Bioprobes. These newly identified biomarkers are modified forms of specific circulating blood proteins that, when used in combination, yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction. "We are very excited about these biomarkers because they clearly demonstrate the significance of protein microheterogeneity in human disease, which has been largely unexplored niche in human molecular biology," adds Kiernan.

Intrinsic Bioprobes Inc. (IBI), located in Tempe, AZ, performs unbiased discovery, verification and population studies on full-length proteins, and discovers and defines microheterogeneity in disease-associated biomarker proteins within healthy and disease populations. IBI's principal focus is the development and application of clinical and diagnostic assays and platforms for rapid and sensitive protein biomarker analysis for early detection and efficient treatment of critical human diseases. IBI's advanced technologies are patented and proprietary process platforms and approaches for proteomic and other research and clinical applications that generally leverage advanced mass spectrometry technology. These approaches include IBI's MASSAY(R) technology system, its Mass Spectrometric Immunoassay (MSIA(TM)) technology and its Bioreactive Probes (BRP(TM)). The Company has developed a deep and growing base of intellectual property in its field, consisting of 19 issued patents and numerous pending patent applications.

For more information about Intrinsic Bioprobes Inc., please visit http://www.intrinsicbio.com.Contact: Dobrin NedelkovIntrinsic Bioprobes Inc.Tel. (480) 804-1778E-mail: info@intrinsicbio.comThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Intrinsic Bioprobes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast
3. Baxa Corporation Announces 2011 Course Schedule for its STAR Center® Training Facility
4. Baltimores Mark E. Spier, DPM, Announces FDA Clearance of PinPointe™ FootLaser™ for Treatment of Nail Fungus
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
6. Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call
7. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
8. NCPA Announces Partnership with Live Oak Bank to Help Finance Independent Community Pharmacy Purchases
9. Trius Announces Issuance of Key U.S. Patent for Torezolid Phosphate
10. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
11. Roper Industries Announces Record Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):